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Abstract 
Live-vaccine delivery systems expressing two model antigens from Mycoplasma hyopneumoniae, 
F2(P97) (Adh) and NrdF, were constructed using Salmonella enterica serovar Typhimurium aroA (STM-1), 
and immunogenicity in mice was evaluated. Recombinant plasmid-based expression (PBE) and 
chromosomally based expression (CBE) systems were constructed. The PBE system was formed by 
cloning both antigen genes into pJLA507 to create an operon downstream of temperature-inducible 
promoters. Constitutive CBE was achieved using a promoter-trapping technique whereby the 
promoterless operon was stably integrated into the chromosome of STM-1, and the expression of 
antigens was assessed. The chromosomal position of the operon was mapped in four clones. Inducible 
CBE was obtained by using the in vivo-induced sspA promoter and recombining the expression construct 
into aroD. Dual expression of the antigens was detected in all systems, with PBE producing much larger 
quantities of both antigens. The stability of antigen expression after in vivo passage was 100% for all CBE 
strains recovered. PBE and CBE strains were selected for comparison in a vaccination trial. The vaccine 
strains were delivered orally into mice, and significant systemic immunoglobulin M (IgM) and IgG 
responses against both antigens were detected among all CBE groups. No significant immune response 
was detected using PBE strains. Expression of recombinant antigens in S. enterica serovar Typhimurium 
aroA from chromosomally located strong promoters without the use of antibiotic resistance markers is a 
reliable and effective method of inducing a significant immune response. 
Keywords 
Development, non, antibiotic, resistant, chromosomally, based, constitutive, inducible, expression, 
systems, for, aroA, attenuated, salmonella, enterica, serovar, typhimurium 
Disciplines 
Life Sciences | Physical Sciences and Mathematics | Social and Behavioral Sciences 
Publication Details 
Matic, J. N., Terry, T. D., Van Bockel, D., Maddocks, T., Tinworth, D., Jennings, M. P., Djordjevic, S. P. & 
Walker, M. J. (2009). Development of non-antibiotic-resistant, chromosomally based, constitutive and 
inducible expression systems for aroA-attenuated salmonella enterica serovar typhimurium. Infection and 
Immunity, 77 (5), 1817-1826. 
Authors 
Jake Matic, Tamsin D. Terry, David Van Bockel, Tracy A. Maddocks, David Tinworth, Michael Jennings, 
Steven P Djordjevic, and Mark J. Walker 
This journal article is available at Research Online: https://ro.uow.edu.au/scipapers/3514 
Infection and Immunity, May 2009, p. 1817-1826 
0019-9567/09/$08.00+0 doi:10.1128/IAI.01301-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Vol. 77, No. 5
Development of Non-Antibiotic-Resistant, Chromosomally Based, 
Constitutive and Inducible Expression Systems for aroA-Attenuated 
Salmonella enterica Serovar Typhimuriumv
Jake N. Matic,1,2 Tamsin D. Terry,3 David Van Bockel,1,2 Tracy Maddocks,1 David Tinworth,4 
Michael P. Jennings,3 Steven P. Djordjevic,2 and Mark J. Walker1*
School o f Biological Sciences, University o f Wollongong, Wollongong, NSW, Australia1; Elizabeth Macarthur Agricultural Institute, 
Menangle, NSW, Australia2; School o f Molecular and Microbial Sciences, University o f Queensland, Brisbane, 
Queensland, Australia2’; and Bioproperties, Melbourne, Victoria, Australia4
Received 24 October 2008/Returned for modification 18 Decem ber 2008/Accepted 9 February 2009
Live-vaccine delivery systems expressing two model antigens from Mycoplasma hyopneumoniae, F2P97 (Adh) 
and NrdF, were constructed using Salmonella enterica serovar Typhimurium aroA (STM-1), and immunoge- 
nicity in mice was evaluated. Recombinant plasmid-based expression (PBE) and chromosomally based expres­
sion (CBE) systems were constructed. The PBE system was formed by cloning both antigen genes into pJLA507 
to create an operon downstream of temperature-inducible promoters. Constitutive CBE was achieved using a 
promoter-trapping technique whereby the promoterless operon was stably integrated into the chromosome of 
STM-1, and the expression of antigens was assessed. The chromosomal position of the operon was mapped in 
four clones. Inducible CBE was obtained by using the in vivo-induced sspA promoter and recombining the 
expression construct into aroD. Dual expression of the antigens was detected in all systems, with PBE 
producing much larger quantities of both antigens. The stability of antigen expression after in vivo passage was 
100% for all CBE strains recovered. PBE and CBE strains were selected for comparison in a vaccination trial.
The vaccine strains were delivered orally into mice, and significant systemic immunoglobulin M (IgM) and IgG 
responses against both antigens were detected among all CBE groups. No significant immune response was 
detected using PBE strains. Expression of recombinant antigens in S. enterica serovar Typhimurium aroA from 
chromosomally located strong promoters without the use of antibiotic resistance markers is a reliable and 
effective method of inducing a significant immune response.
The use of live, attenuated bacteria as vaccine delivery sys­
tems for heterologous antigens has been extensively studied. In 
particular, attenuated Salmonella strains have been modified 
to express a wide range of antigens from bacterial, parasitic, 
and viral sources (reviewed in references 20, 29, and 41). After 
oral administration, Salmonella can penetrate the Peyer’s 
patches via M cells and colonize the mesenteric lymph nodes, 
which contain various antigen-presenting cells (reviewed in 
reference 5). This can generate a range of immune responses, 
including systemic and mucosal responses at local and distal 
sites. O ther advantages of using attenuated Salmonella include 
the ease of oral administration, which bypasses the need for 
needle administration; increased antigen presentation due to 
the use of a live-vector delivery system, the induction of both 
T h l and Th2 immune responses; and the wide range of atten­
uated Salmonella and recombinant vectors available to re­
searchers (19, 20, 51).
However, there are a number of issues to overcome. Most 
methods for the expression of heterologous antigens in Salmo­
nella use plasmids to express the antigenic proteins. This can 
have several drawbacks. The stable maintenance of the expres­
sion plasmid in vivo can be difficult to achieve. Tightly regu­
lated promoters are often used to increase plasmid stability,
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and several in vivo-inducible promoters have delivered prom ­
ising results. Oral delivery of flroTD-attenuated Salmonella 
enterica serovar Typhimurium expressing the C fragment of 
tetanus toxin from nirBp was able to protect mice from lethal 
tetanus challenge (6). O ther in vivo-inducible promoters, such 
as pagCp, sspAp, and ssaGp, have also been used in aroAD- 
attenuated S. enterica serovar Typhimurium to generate te ta­
nus toxoid-specific and heat-labile toxin B immune responses 
in mice (12, 35, 48).
Instability may arise through the extra metabolic burden 
associated with a high-copy-number plasmid, leading to the 
selection of variants that have lost the plasmid during growth. 
In vitro, plasmids can be maintained through the use of anti­
biotic resistance markers; however, this is not feasible under 
field conditions, with emerging antibiotic resistance a global 
health issue. In order for these vaccines to be used in a com­
mercial human or veterinary setting, the antibiotic resistance 
genes must be removed, although a selection mechanism for 
the maintenance of plasmids during vaccine production would 
still be required (48). One method for nonantibiotic mainte­
nance of plasmid vectors is the use of the asd vector/A.asd host 
lethality system, in which the attenuated S. enterica serovar 
Typhimurium has an obligatory requirem ent for diamin- 
opimelic acid that is complemented by the vector (39). N on­
antibiotic resistance markers have also been developed, including 
bar, which encodes resistance to the herbicide DL-phosphino- 
thricin (38); merA, which provides resistance to organomercu- 
rial compounds (21); and arsAB, which express arsenite resis-
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TABLE 1. Bacterial strains and plasmids used in this study
Bacterial strain/plasmid Characteristics Source
E. coli 
JM109
M15(pREP4)
S. enterica serovar Typhimurium 
STM-1 
JA08
STM-AN1
STM-AN2
STM-AN3
STM-AN4
STM-sspA
endAl recAl gvrA96 thi-1 hsdR17(rK~ mK~) relAl supE44 A(lac-proAB) [F ' traD36 52
proAB  toc/qZAM15]
Derivative of E. coli K-12; contains kanamycin-resistant pREP4, ensuring the production Qiagen 
of high levels of lac repressor protein
fl/'oA-attenuated strain 1
Laboratory-passaged STM-1 strain; streptomycin sensitive, rifampin resistant 48
Chromosomal insertion of the nrdF-adh operon into dps of STM-1 This study
Chromosomal insertion of the nrdF-adh operon into glgP of STM-1 This study
Chromosomal insertion of the nrdF-adh operon into orfl of STM-1 This study
Chromosomal insertion of the nrdF-adh operon into tral of STM-1 This study
Chromosomal insertion of the nrdF-adh operon with sspAp into aroD of JA08 This study
M. hyopneumoniae J Laboratory-passaged nonvirulent strain 44
Plasmids
pJLA506 Ampicillin-resistant expression vector containing PlPr prom oters and atpE  ribosome 
binding sites
45
pJLA507 pJLA506 with an XhoI-NcoI-EcoRI polylinker inserted into the EcoRI site This study
pJLA507-A pJLA507 with M. hyopneumoniae adh gene cloned between Ndel and Sail sites This study
pJLA507-N pJLA507 with M. hyopneumoniae nrdF gene cloned between Ndel and Sail sites This study
pJLA507-AN pJLA507-N with M. hyopneumoniae adh gene cloned into Sail site This study
pUC18-NotI Identical to pUC18 but with N otl-EcoR I-Sall-H indlll-N otl as multiple-cloning site 24
pUC18-AN pUC18-NotI with promoterless nrdF-adh operon cloned into Notl This study
pUT/Ars Apr; Tn5-based delivery plasmid with arsA and arsB 24
pArs-AN pUT/Ars with promoterless nrdF-adh operon cloned into Notl site This study
pKKsspATetC sspA prom oter cloned into pKK233-2 48
pKKsspA-AN pKKsspA with nrdF-adh operon cloned between N col/H indlll sites This study
pCVDaroDins pCVD442 with 5' and 3' sections of S. enterica aroD 48
pCVD-AN pCVDaroDins with sspAp-nrdF-adh-nnBt cassette cloned into SphI and SacI This study
pF2P97 His-tagged F2P97 expression vector based on pQE9 27
pK Fl His-tagged NrdF expression vector based on pQE9 16
tance proteins (9). Plasmid-based expression (PBE) systems 
can express antigens at high levels; however, high levels of 
expression of some antigens can have a growth-inhibitory effect 
(10, 51) and thus can reduce the eflhcacy of the live delivery 
system.
To overcome some of the problems associated with PBE 
systems, heterologous antigen expression cassettes have been 
integrated into the Salmonella chromosome (25, 47). The chro- 
mosomally integrated constructs have been examined as vac­
cines in several studies and were shown to elicit a protective 
immune response, although generally the level of antigen ex­
pression is much lower than in plasmid-based systems (20).
In this study, we used two Mycoplasma hyopneumoniae an­
tigens, F2P97 (hereafter referred to as Adh) and ribonucleotide 
reductase (NrdF), in a screen to identify novel promoters use­
ful for antigen expression in S. enterica serovar Typhimurium 
from single-copy chromosomal constructs. M. hyopneumoniae 
is a pathogen of swine that colonizes the ciliated epithelial cells 
of the respiratory tract and causes significant economic losses 
(11). Adh and NrdF have both been previously studied in 
vaccination experiments when expressed from plasmid-based 
systems in S. enterica serovar Typhimurium aroA (7, 8, 15, 16, 
17). Oral vaccination with NrdF-expressing S. enterica serovar 
Typhimurium aroA has resulted in significant immunoglobulin 
A  (IgA) responses in murine lungs (16), increased murine 
splenocyte NrdF-specific gamma interferon (IFN-y) produc­
tion (7), and primed the porcine respiratory tract for an NrdF- 
specific secretory IgA response (17). Adh-stimulated spleno- 
cytes from mice orally vaccinated with S. enterica serovar 
Typhimurium aroA expressing Adh showed increased IFN-y 
production (8 ). The constructs generated in this study, which 
expressed both antigens in tandem, were used to orally vacci­
nate mice, and the immune responses were evaluated.
MATERIALS AND METHODS
Growth of bacterial strains and isolation of genomic and plasmid DNA. The
bacterial strains and plasmids used in this study are listed in Table 1. M. hyo­
pneumoniae was grown in Friis medium as previously described (18). Escherichia 
coli and S. enterica serovar Typhimurium strains were grown in Luria-Bertani 
(LB) medium supplemented with antibiotics, where appropriate, at 37°C. Anti­
biotics were used at the following concentrations: ampicillin, 100 jxg/ml; chlor­
amphenicol, 50 |xg/ml: kanamycin, 50 pg/nil: rifampin (rifampicin), 100 fxg/nil; 
and streptomycin, 100 fxg/nil. Growth curve analysis with minimal medium sup­
plemented with aromix was performed as previously described (33).
Plasmid DNA was isolated using the Wizard Plus SV Miniprep kit (Promega, 
Australia) according to the manufacturer’s instructions. Isolation of genomic 
DNA was achieved using the DNeasy Blood and Tissue Kit (Qiagen, Australia) 
according to the manufacturer’s instructions.
For protein expression, His6-tagged Adh (27) and NrdF (16) expression vec­
tors were used. E. coli cultures were grown to an optical density at 560 run 
(OD560) of 0.8 at 37°C, induced with isopropyl thiogalactopyranoside at a final 
concentration of 1 mM, and grown for a further 4 h. The cells were pelleted at 
5,000 X g for 10 min, and the recombinant protein was purified using nickel- 
nitrilotriacetic acid resin (Qiagen) as specified in the manufacturer’s instructions.
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FIG. 1. Cloning schematic for the production of PBE and CBE constructs. E, EcoRI; H, H indlll; N, Ndel; Nc, Ncol; Nt, Notl; S, Sail; X, Xhol; 
atpE, atpE ribosome binding site; rrnBto, E. coli rRNA terminator; tnp, transposase. The diagram is not to scale.
Construction of recombinant plasmids. Restriction enzyme digestions and 
DNA ligations were performed according to standard procedures (43). To con­
struct pJLA507-AN, nrdF was PCR amplified from M. hyopneumoniae strain J 
DNA using the primers 5,-GGCATATGGATCTATTATATAAACTAATT-3/ 
and 5 '-GGGTCGACTTAAAACTCCCAATCTTCATG-3'. This PCR product 
encompassed the DNA encoding the 11-kDa carboxy terminus of NrdF. The adh 
gene was PCR amplified from M. hyopneumoniae strain J DNA using the primers 
5' - GGCAT AT G AAATTAG ACG AT AAT CTT CAG-3' and 5 '-GGGT CG ACT 
TAAGGATCACCGGATTTTGAA-3'. This PCR product encompassed the 
DNA encoding an approximately 36-kDa segment of P97 incorporating both 
C-terminal repeat regions and is referred to as Adh. The PCR products and 
pJLA507 were digested with Ndel and Sail, ligated, and transformed into E. coli 
JM109. Potential clones were screened using digoxigenin (Dig)-labeled probes in 
a colony hybridization screening procedure according to the manufacturer’s 
instructions (Roche, Australia). Plasmid pJLA507-A was then digested with 
Xhol and Sail to release the adh gene, which was then subcloned into the Sail 
site of pJLA507-N to yield pJLA507-AN. To construct pARS-AN, pJLA507-AN 
was digested with EcoRI and Hindlll to release the nrdF-adh operon, which was
then subcloned into pUClSNotl to create pUC18NotI-AN. Plasmid 
pUC18NotI-AN was digested with Notl, and the nrdF-adh operon was cloned 
into the Notl site of pUT/Ars (24) to form pARS-AN and subsequently trans­
formed into E. coli CC118 Xpir (Fig. 1).
Construction of the sspA chromosomal expression strain began with digesting 
pJLA507-AN with Ncol and Hindlll and then subcloning the promoterless 
nrdF-adh operon into the Ncol and Hindlll sites of pKKsspATetC to form 
pKKsspA-AN. The region from sspAp to the rmB terminator sequence (includ­
ing the nrdF-adh operon) was PCR amplified using primers 5'-GTCGAAAGC 
TT GTCGACTT AAGGA-3' and 5' -G ACT CCCATGG AT CT ATT AT AT AAAC 
T-3'. pCVDaroDins was digested with SphI and SacI, and the PCR product was 
ligated into these sites to form pCVD-AN.
PCR amplification of the nrdF-adh operon for screening purposes was 
performed using 5' -G GC AT AT G GAT CT ATT AT AT AAACT AATT-3' and 
5 ' -GGGTCG ACTT AAGGAT CACCGGATTTT GAA-3'.
Conjugation and arsenic resistance screening. pARS-AN was transformed 
into E. coli SM10 Xpir. S. enterica serovar Typhimurium STM-1 was mated with 
SM10 X/?ir(pARS-AN) overnight on LB agar at 37°C. Prior to being plated onto
1820 MATIC ET AL. I n f e c t . I m m u n .
selective arsenite [As(III)] medium, the mating mixture was subjected to phos­
phate starvation. This was achieved by growing the mating mixture for 24 h with 
shaking at 37°C in 200 ml of minimal phosphate buffer (50 mM MOPS [mor- 
pholinepropanesulfonic acid], 50 mM KC1, 0.8 mM MgS04, 0.8 mM C a d 2, 0.3 
mM KH2P 0 4, 0.5 g/liter sodium citrate, 1 g/liter [NH4]2S 0 4, 36 pM FeS04). 
As(III)-resistant colonies were then selected on LB agar plates supplemented 
with streptomycin, 100 pM 2,2' bipyridyl, and 2 mM As(III) for 96 h at 37°C. To 
discriminate between genuine transposition events and illegitimate recombina­
tion events, arsenite-resistant colonies were screened for the loss of the ampi- 
cillin resistance marker by examining sensitivity to ampicillin.
Conjugation of pCVD-AN into S. enterica serovar Typhimurium JA08 (a 
rifampin-resistant, streptomycin-sensitive derivative of STM-1) was performed as 
previously described (48). Selection for double crossovers using lacZ color se­
lection was performed as previously described (48). The double crossovers were 
confirmed via PCR, and the double-crossover strain was desiguated STM-sspA.
Colony immunoblotting screening for antigen expression. Colony irnmuno- 
blotting was performed essentially as previously described (43). The colonies to 
be screened were picked and patched onto the appropriate agar plates and grown 
overnight at 37°C. The colonies were lifted onto a nitrocellulose membrane. The 
nitrocellulose was exposed to chloroform vapor for 15 min in an airtight glass 
container. The colonies were lysed overnight at room temperature with gentle 
agitation in lysis buffer (100 mM Tris-HQ, pH 7.8,150 mM NaCl, 5 mM MgQ2, 
1 pg/ml DNase I, 40 pg/ml lysozyme). The nitrocellulose membranes were then 
washed twice for 30 min each time in phosphate-buffered saline (PBS) (8 g/liter 
N ad , 0.2 g/liter KC1, 1.15 gditer Na2H P 04, 0.2 gditer KH2P 0 4) and blocked 
with PBS-5% skim milk for 1 h at room temperature with gentle agitation. The 
primary antibody was diluted 1:1,000 in PBS-1% skim milk and applied to the 
membranes for 2 to 4 h at room temperature with gentle agitation. The mem­
branes were then washed three times in PBS for 10 min per wash, and the 
appropriate secondary antibody was diluted 1:1,000 in PBS-1% skim milk. The 
membrane was incubated with the secondary-antibody solution for 2 h at room 
temperature with gentle agitation, followed by three 10-min washes in PBS. The 
membrane was equilibrated in 100 mM Tris-HCl (pH 7.6) for 2 min and devel­
oped in diaminobenzidene developing solution (50 mg diaminobenzidine, 50 ml 
Tris-HCl, pH 7.6, 30 pi H20 2) until sufficient color was obtained. The reaction 
was then stopped by immersing the membrane in distilled H20 .
Inverse PCR and Southern hybridization analyses. Chromosomal DNA was 
isolated from S. enterica serovar Typhimurium strains using the DNeasy Blood 
and Tissue Kit (Qiagen, Australia) according to the manufacturer’s instructions. 
DNA was digested with the appropriate restriction enzymes (Fermentas, Aus­
tralia), followed by heat inactivation according to the manufacturer’s instruc­
tions. Chromosomal DNA was then religated overnight in a final volume of 100 
pi as described previously. Inverse PCR was then performed using the primer 
sequences 5 '-TCAATTAGTTTATATAATAGATCC-3' and 5'-TTAGTCAAT 
TATCGGCTCG-3', which were outward-facing sequences based on the adh and 
nrdF genes, respectively. The PCR products were DNA sequenced as previously 
described (37).
Southern transfer was performed as previously described (43). Dig-labeled 
nrdF PCR products were used as probes, and Southern hybridization analysis was 
performed according to the manufacturer’s instructions (Roche, Australia).
Induction of PBE strains and expression stability. S. enterica serovar Typhi­
murium STM-1 strains harboring the pJLA507 series of constructs were grown in 
a 10-ml LB starter culture overnight at 37°C. The entire starter culture was used 
to inoculate a 50-ml LB culture, and the OD560 was adjusted to 0.4 with LB. The 
strains were grown for 1 h at 37°C. Induction was achieved by culturing the 
strains at 42°C. Growth curves in minimal medium supplemented with aromix 
were performed as previously described (33).
SDS-PAGE and Western blot analyses. Sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis (SDS-PAGE) gels were run as described by Sambrook 
et al. (43) and stained with Coomassie brilliant blue. For Western blot analysis, 
SDS-PAGE gels were electrophoresed but not stained. The samples were nor­
malized by culture amount and visual analysis on Coomassie-stained SDS-PAGE 
so that equivalent amounts were loaded in each lane. Western transfer and 
membrane blotting were performed as previously described (15). The membrane 
was then developed in diaminobenzidene developing solution (50 mg diamino­
benzidine, 50 ml Tris-HCl, pH 7.6, 30 pi H20 2) until sufficient color was ob­
tained. The reaction was then stopped by immersing the membranes in distilled 
H20 . Alternatively, membranes were developed using a SuperSignal West Pico 
chemiluminescent substrate kit (Pierce, Australia) according to the manufactur­
er’s instructions. For pooled sera, the highest-responding mouse in each chro- 
mosomally based expression (CBE)-immunized group (as determined by en­
zyme-linked immunosorbent assay [ELISA] IgG response against Adh) was
selected. Equal volumes of sera from these mice were then pooled, diluted 1:50, 
and used in Western blot analysis.
Animal immunization procedures. Six-week-old female BALB/c mice were caged 
separately according to treatment groups (10 mice per group). For live oral vacci­
nations, CBE cultures were grown to an OD560 of 1.0 and pelleted at 5,000 X g for 
10 min. PBE cultures were induced at 42°C for 4 h and pelleted at 5,000 X g for 10 
min. All oral vaccination strains were then resuspended in ice-cold PBS with 5% 
sucrose to an OD corresponding to 1 X 109 viable cells per 100 pi. The mice were 
deprived of drinking water for 3 h prior to oral immunization. After 3 h, the mice 
were orally immunized with a single 100-pi dose containing 1 x 109 viable cells 
delivered behind the incisors using a pipette tip. For intraperitoneal immuniza­
tion, 50 pg of purified Adh or NrdF was diluted to a total volume of 50 pi in PBS 
and then mixed with an equal volume of Freund’s incomplete adjuvant. The mice 
were then immunized with a 100-pi dose.
A  total of three immunizations were performed for both the oral and intra­
peritoneal groups, each given 2 weeks apart. Two weeks after the final immuni­
zation, five mice in each group were euthanized with C 0 2 and exsanguinated by 
severing the brachial artery (day 42). Sera were collected and stored at -20°C. 
Lung wash samples were taken using 500 pi PBS containing 2 pM phenylmeth- 
ylsulfonyl fluoride and stored at -20°C. The remaining five mice in each group 
were given an intranasal antigen challenge 2 weeks later (day 56) consisting of 5 
pg of Adh and 5 pg of NrdF in PBS (total volume, 10 pi). These mice were 
exsanguinated as described above 2 weeks after antigen challenge (day 70).
The generation of rabbit polyclonal NrdF and Adh antisera was performed as 
previously described (31).
To determine the in vivo stability of the STM-1 strains, five mice per group 
were orally inoculated with 1 X 109 CFU as described above. Ten days after 
inoculation, the mice were exsanguinated as described above and the spleens 
were removed. The spleens were homogenized in 5 ml ice-cold PBS and plated 
onto LB-rifampin (STM-sspA) or LB-streptomycin (all other strains). The total 
CFU were calculated, and 50 colonies (10 colonies per mouse) were randomly 
selected for further analysis. Southern blotting was performed as described above 
using a Dig-labeled nrdF probe to detect the presence of the operon. Western 
blotting was performed as described above with rabbit polyclonal Adh antisera.
ELISA protocols and statistical analysis. ELISA was performed as previously 
described (16), and the results were analyzed using Softmax Pro 4.0 software 
(Molecular Devices, Australia). For whole-cell ELISA, STM-1 was streaked onto 
an agar plate and grown overnight at 37°C. A  single colony was then used to 
inoculate 10 ml of LB and was grown in a 37°C shaking incubator until an OD600 
of 1 was reached. The cells were pelleted at 5,000 X g for 10 min at 4°C, and the 
supernatant was discarded. The pellet was then resuspended in 10 ml of PBS- 
10% methanol. The cells were dispensed into 1-ml aliquots and stored at -20°C 
until they were required. The cells were thawed on ice, and 96-well ELISA plates 
(Interpath, Australia) were then coated with 50 pi of cells per well. The 96-well 
plates were centrifuged at 420 X  g for 10 min at room temperature. The solution 
in the wells was removed, and the plates allowed to air dry. The plates were then 
blocked, incubated, and developed as described above.
Statistical significance was determined using a Student t test by comparison of 
each trial group to the PBS-negative control group. A P value of <0.05 was 
considered to be significant.
RESULTS
Construction of PBE strains. The goal of this study was to 
identify promoters useful for antigen expression in S. enterica 
serovar Typhimurium. We devised a genetic screen using two 
M. hyopneumoniae antigens, Adh (F2P97) and NrdF. The adh 
gene encodes a domain containing both repeat regions of P97 
(27). P97 is a proteolytically processed adhesin protein capable 
of binding swine cilia (11, 53). NrdF has been extensively 
studied as a putative vaccine candidate, and previous vaccina­
tion studies have demonstrated that NrdF can invoke T h l and 
Th2 immune responses and improve the average daily weight 
gain of swine challenged with M. hyopneumoniae (7, 16, 17).
The cloning scheme of the PBE constructs is outlined in Fig. 
1. NrdF  and adh antigens were PCR amplified from M. hyo­
pneumoniae chromosomal DNA and flanked with N del and 
Sail restriction sites, which facilitated cloning into pJLA507 to 
produce pJLA507-A (containing adh) and pJLA507-N (con­
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taining nrdF). The pJLA507-A vector was digested with Xhol/ 
Sail, and adh was subcloned into the Sail site of pJLA507-N to 
produce pJLA507-AN. Plasmid pJLA507-AN is capable of ex­
pressing both antigens as individual proteins from the tem per­
ature-inducible PLPR prom oter (45).
Construction of CBE strains. In order to attain antigen 
expression from single-copy non-antibiotic-resistant chromo­
somal constructs in S. enterica serovar Typhimurium, CBE 
systems were engineered. Initially the promoterless nrdF-adh 
operon from pJLA507-AN was subcloned into pUC18/Vof, 
which flanked the nrdF-adh operon with N otl sites. Plasmid 
pUC18NotI-AN was digested with Notl, and the nrdF-adh 
operon was subcloned into pUT/Ars to produce pARS-AN 
(Fig. 1). Plasmid pARS-AN was then transformed into SM10 
Xpir, and a promoter-trapping experiment was performed 
whereby SM10 Xpir(pARS-AN) was mated with S. enterica 
serovar Typhimurium STM-1. A  total of 1,200 arsenite-resis- 
tant, ampicillin-sensitive STM-1 transconjugants were screened 
for the expression of Adh via colony immunoblotting (results 
not shown), and four highly expressing transconjugants were 
selected for further characterization. The presence of the nrdF- 
adh operon in the chromosomes of arsenite-resistant, Adh- 
expressing STM-1 colonies was confirmed using PCR and 
Southern hybridization analyses (Fig. 2).
To construct the sspA chromosomal expression strain, 
pJFA507-AN was digested with Ncol and H indlll, and the 
promoterless nrdF-adh operon was subcloned into the Ncol 
and H ind lll sites of pKKsspA to form pKKsspA-AN. The 
region from psspA to irnBt, including the nrdF-adh operon, was 
PCR amplified and flanked with SphI and SacI sites. pCVDaro- 
Dins was digested with SphI and SacI, and the PCR product 
was cloned between these sites to form pCVD-AN (Fig. 1). 
pCVD-AN was transformed into E. coli S17.1 Xpir and mated 
with STM-1 JA08. Double crossovers were selected using lacZ 
color screening, putative double crossovers were confirmed via 
PCR (Fig. 2), and a selected strain was designated STM-sspA.
Characterization of STM-1 expression strains. Inverse PCR 
was perform ed to examine the insertion point of the nrdF-adh 
operon in the chromosome of STM-1 to determine which pro­
moters were driving antigen expression. Once inverse-PCR 
products were generated, DNA sequence analysis was used to 
determine the point of insertion (Fig. 2). Briefly, expression of 
NrdF and Adh in STM-AN1 was under the control of the dps 
promoter. The dps gene encodes a DNA binding protein, 
which provides starvation-induced resistance to hydrogen per­
oxide (22). In STM-AN2, the nrdF-adh operon has been 
inserted into the glycogen metabolism operon, namely, the 
glycogen phosphorylase gene,glgP (2). In STM-AN4, the nrdF- 
adh operon has been inserted into a gene required for conjugal 
transfer, tral.
DNA sequence analysis of the inverse-PCR product ob­
tained for STM-AN3 revealed that the construct had been 
inserted into a novel DNA sequence that showed no homology 
to any known Salmonella genome sequence. In order to con­
firm the existence of this novel sequence in STM-1, PCR prim ­
ers were designed based on the sequence, and a PCR product 
was amplified from the genome of the original parental strain, 
STM-1 (data not shown). The PCR product was sequenced 
and was a 100% match to the original inverse-PCR product 
from STM-AN3 (data not shown). The sequence was assessed
ompX ybiF dpsnrdF adh arsB arsA dps glnH glnP
glgC glgA glgPnrdF adh arsB arsA glgP STM 3533
STM-AN2
ortt oifl oifl nrdF adh arsB arsA
STM-AN3
STM-AN4
STM-sspA
ydiB aroD nrdF adh rmB aroD ydiF
lkb
FIG. 2. Chromosomal locations of antigen gene constructs. 
(A) Southern hybridization analysis of H indlll-digested chromosomal 
DNA from STM-1 vaccine strains using a Dig-labeled nrdF  probe. 
Lanes: 1, STM-1; 2, STM-AN1; 3, STM-AN2; 4, STM-AN3; 5, STM- 
AN4. Molecular size markers in kb are indicated on the left. (B) PCR 
of the nrdF-adh operon from the chromosomes of STM-1 vaccine 
strains. Lanes: 1, STM-1; 2, STM-AN1; 3, STM-AN2; 4, STM-AN3; 5, 
STM-AN4; 6, STM-sspA. Molecular size markers in kb are indicated 
on the left. (C) Chromosomal locations of the nrdF-adh operon within 
STM-1 vaccine strains as determined using inverse PCR. Gene names 
are indicated, adh, M. hyopneumoniae F2P97; aroD, 3-dehydroquinase; 
arsA, arsenite-translocating ATPase; arsB, arsenite efflux membrane 
protein; dps, stress response DNA binding protein; finO , FinP binding 
protein; glgA, glycogen synthase; glgC, glucose-l-phosphate adenylyl- 
transferase;g/gP, glycogen phosphorylase; glnH, high-affinity glutamine 
transport protein; glnP, glutamine transport permease protein; nrdF, 
M. hyopneumoniae ribonucleotide reductase; ompX, outer membrane 
protein X; orf, hypothetical open reading frame; psspA, prom oter for 
stringent starvation protein A; rrnB, E. coli rR N A  terminator; 
STM3533, putative transcriptional regulator; tral, OriT nickase/heli- 
case; traX, pilin subunit acetyUtion; trbH, conjugative-transfer protein; 
vbiF, putative permease; vdiB, quinate/shikimate dehydrogenase; vdiF, 
putative acetyl-coenzyme A  (CoA)/acetoacetyl-CoA transferase beta 
subunit. The scale in kb is indicated.
for putative open reading frames. A  putative open reading 
frame (oifl)  was found, and a Blastx search was performed. 
The sequence was 100% homologous to a hypothetical protein 
from Ralstonia solanaceamm  (accession number AL646052.1) 
(42). Analysis of other putative open reading frames (or/2 and 
oif3) revealed significant amino acid matches (99% and 100%, 
respectively) to other hypothetical Ralstonia pickettii proteins.
Expression profiles of PBE and CBE strains. A comparison 
of the expression profiles of the recombinant constructs was 
performed. The expression of NrdF and Adh from STM- 
l(pJLA507-AN) is presented in Fig. 3. SDS-PAGE revealed a
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FIG. 3. Growth curve and W estern blot analyses of expression from STM-l(pJLA507-AN) and CBE strains. (A and B) W estern blot of 
whole-cell lysates of STM-l(pJLA507-AN) using rabbit polyclonal Adh antisera (A) and rabbit polyclonal NrdF antisera (B). Lane 1, STM- 
l(pJLA507-AN) preinduction; lane 2, STM-l(pJLA507-AN) 1 h postinduction; lane 3, STM-l(pJLA507-AN) 2 h postinduction; lane 4, STM- 
l(pJLA507-AN) 4 h postinduction; lane 5, purified His-tagged Adh (200 ng) (A) or purified His-tagged NrdF (5 to 10 pg) (B). (C) W estern blot 
analysis of whoie-cell lysates of CBE strains using rabbit polyclonal Adh antisera. Lane 1, STM-1; lane 2, STM-AN1; lane 3, STM-AN2; lane 4, 
STM-AN3; lane 5, STM-AN4. Molecular mass markers in kDa are shown on the left. (D) Growth curve analysis of PBE strains performed in LB. 
The strains were grown at 37°C for 1 h prior to induction at 42°C, indicated by the arrow. (E) Growth curves of CBE strains performed in minimal 
medium supplemented with aromix.
protein with an apparent molecular mass of 36 kDa evident 1 h 
postinduction (data not shown). W estern blot analysis showed 
that the protein reacted with polyclonal Adh antiserum. Ex­
pression of the 11-kDa C terminus of NrdF was not apparent 
using SDS-PAGE (data not shown). However, Western blot­
ting with polyclonal NrdF antiserum detected the expression of 
an 11-kDa band, confirming the expression of NrdF in STM- 
l(pJLA507-AN).
The expression profiles of the CBE strains are also displayed 
in Fig. 3. Neither Adh nor NrdF expression could be visualized 
using SDS-PAGE with Coomassie brilliant blue (data not 
shown). Western blot analysis with polyclonal Adh antisera 
revealed the presence of a 36-kDa band corresponding to the 
correct mass of Adh in all CBE strains, with the exception of 
STM-sspA (data not shown). NrdF expression was faintly de­
tected in the majority of the CBE strains, indicating that ex­
pression of NrdF was occurring but that the level of expression 
was at the very limit of detection (data not shown).
In vitro growth and stability of expression. Growth curves of 
the CBE and PBE strains were perform ed to determine what 
effect the genetic manipulations had on the various strains’ 
abilities to replicate in vitro (Fig. 3). The PBE strains were 
grown at mid-log phase for 1 h before induction at 42°C. 
Shortly after induction, two of the PBE strains, STM- 
l(pJLA507-N) and STM-1 (pJLA507-AN), had static levels of 
growth. Both of the strains express NrdF, suggesting that the 
production of NrdF had a growth-inhibitory effect on STM-1. 
CFU counts were conducted, which confirmed that the over­
expression of NrdF had a bacteriostatic effect on STM- 
l(pJLA507-N) and STM-1 (pJLA507-AN) (data not shown).
Growth curves of the CBE strains were perform ed in mini­
mal medium supplemented with aromix to ensure that the
insertion of the nrdF-adh operon into the chromosome of 
STM-1 did not further attenuate the strains. Analysis of growth 
revealed that one strain, STM-AN1, replicated at a much lower 
rate than the other strains (Fig. 3). This indicated that the 
insertion of the nrdF-adh operon into the dps gene attenuated 
the growth of this strain in minimal medium, making it unsuit­
able for subsequent vaccination trial experiments.
The stability of antigen expression from the various PBE and 
CBE strains in vivo was examined. Mice were orally inoculated 
with 1 X 109 CFU, and the spleens were harvested 10 days 
postinoculation. Fifty colonies (10 per mouse) were randomly 
selected for each strain and analyzed by Southern blotting for 
the presence of the operon and by W estern blotting for heter­
ologous antigen expression (Table 2). Colonies were not de­
tected in the spleens for any of the PBE strains or STM-AN2. 
The nrdF-adh operons in colonies that were detected for all 
other CBE strains showed 100% stability, and all colonies 
examined were capable of heterologous antigen expression.
Immune responses of mice following oral vaccination. 
Mouse oral vaccination trials were conducted using the PBE 
and CBE strains. Mice were given either three oral immuni­
zations with S. enterica serovar Typhimurium strains or three 
intraperitoneal vaccinations with purified Adh or NrdF. Four­
teen days after the final vaccination, five mice in each group 
were sacrificed (day 42). As M. hyopneumoniae is not capable 
of infecting mice, immune recall was tested using purified 
recombinant antigens. Two weeks later, the remaining five 
mice were intranasally challenged with purified Adh and NrdF. 
Serum and lung wash responses were determined using ELISA 
(Fig. 4). Statistically significant (P <  0.05) serum IgM re­
sponses against Adh, NrdF, and STM-1 whole cells were de­
tected for all CBE and purified intraperitoneal antigen mice at
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TABLE 2. Stability of the nrdF-adh operon and heterologous antigen 
expression in various S. enterica serovar Typhimurium aroA vaccine 
strains following 10 days of in vivo passage in mice
Strain Mouseno.
Total no. of
CFU
recovered"
Operon
presence
Antigen
expression
STM -A N 2 1 0 N D 6 N D
2 0 N D N D
3 0 N D N D
4 0 N D N D
5 0 N D N D
STM -AN3 1 216 10/10 10/10
2 102 10/10 10/10
3 36 10/10 10/10
4 421 10/10 10/10
5 712 10/10 10/10
STM -A N4 1 37 10/10 10/10
2 65 10/10 10/10
3 65 10/10 10/10
4 167 10/10 10/10
5 16 10/10 10/10
STM -sspA 1 25 10/10 10/10
2 40 10/10 10/10
3 11 10/10 10/10
4 54 10/10 10/10
5 15 10/10 10/10
STM (pJLA 507) 1 0 N D N D
2 0 N D N D
3 0 N D N D
4 0 N D N D
5 0 N D N D
STM (pJLA 507-A ) 1 0 N D N D
2 0 N D N D
3 0 N D N D
4 0 N D N D
5 0 N D N D
STM (pJLA 507-A N ) 1 0 N D N D
2 0 N D N D
3 0 N D N D
4 0 N D N D
5 0 N D N D
" In vivo stability determined by orally inoculating groups of five mice with 1 : 
109 CFU of a single strain. Ten days after inoculation, the spleens were removed.
S. enetrica serovar Typhimurium aroA was selected by plating homogenized 
spleens onto Rif LB agar (STM-sspA) or Sm LB agar (all other strains). Colonies 
were confirmed as S. enterica serovar Typhimurium by streaking them onto 
MacConkey agar. Ten colonies per mouse were randomly selected for further 
analysis. 
b ND, no data.
day 42, but not day 70. No IgM response against Adh or NrdF 
was detected among PBE mice, although there was an IgM 
STM-1 whole-cell response at day 42 (data not shown). Serum 
IgG responses against NrdF and Adh are shown in Fig. 4. A t 
day 42, only the purified-intraperitoneal-antigen- and STM- 
sspA-vaccinated mice had significant IgG responses (P <  0.05) 
against Adh and NrdF. After intranasal challenge (day 70), all 
of the CBE and intraperitoneally vaccinated mice displayed 
significant serum IgG responses (P <  0.05) against both anti­
gens, indicating that a systemic response had been induced. A 
serum IgG response against Adh or NrdF could not be de­
tected at any time point for the PBE mice, although an IgG
response against STM-1 whole cells was detected. The lung 
wash samples from the mice were analyzed for the presence of 
NrdF- and Adh-specific IgA and IgG; however, no significant 
response was detected at any time point (data not shown).
Pooled sera from orally immunized mice prior to intranasal 
challenge (day 42) were used in a W estern blot against M. 
hyopneumoniae (strain J) whole-cell lysate, purified Adh, and 
purified NrdF (Fig. 4). The antiserum recognized a protein of 
approximately 95 kDa in the M. hyopneumoniae whole-cell 
lysate, which corresponds to the mature adhesin protein (27, 
50). The antiserum also recognized the adhesin cleavage prod­
ucts, displaying the characteristic ladder pattern previously ob­
served (28, 50, 53). This antiserum recognized a protein cor­
responding in mass to full-length NrdF (42 kDa) in the M. 
hyopneumoniae whole-cell lysates (15). The antiserum recog­
nized both of the purified antigens, indicating that oral immu­
nization of mice with S. enterica serovar Typhimurium is capa­
ble of eliciting specific serum IgG responses against both of the 
antigens.
DISCUSSION
Oral vaccination of recombinant, attenuated live bacterial 
expression systems is a promising m ethod for heterologous 
antigen delivery. In this study, CBE of M. hyopneumoniae an­
tigens in aroA-attenuated S. enterica serovar Typhimurium 
elicited significant systemic immune responses. This approach 
to vaccine design has a number of advantages that allow it to be 
used for commercial applications. They include the use of 
non-antibiotic resistance markers, a stable expression system, 
low cost of production, and easy administration.
The PBE system used in this study failed to elicit any signif­
icant antigen-specific immune responses. Induction of expres­
sion in the PBE system was perform ed at 42°C so that the PBE 
strains would be loaded with overexpressed antigens upon ad­
ministration. This is in contrast to the CBE strains, which 
expressed NrdF and Adh in vitro at much lower levels. N one­
theless, the CBE strains did elicit significant systemic (IgG and 
IgM) responses in vivo. Lowering the level of heterologous 
antigen expression may reduce the physiological stress on the 
host Salmonella strain, thus increasing the level of colonization 
and immune response (46). Colonies were not detected after 
10 days of passage in vivo for any of the PBE strains examined. 
Expression of the antigens and the extra metabolic burden 
associated with maintaining the plasmid in vivo appear to have 
severely impacted the abilities of these strains to survive in the 
murine spleen, which also may have contributed to the lack of 
an antigen-specific immune response. Dunstan et al. (13) ex­
amined the abilities of aroA- and aroD-attenuated S. enterica 
serovar Typhimurium harboring a range of tetanus toxin frag­
m ent C-expressing plasmids to survive in various murine or­
gans after a single inoculation. The authors found colonies in 
the spleen up to 20 days postinoculation for all vectors exam­
ined, although they used an inoculum 10-fold greater than 
those examined here. This, along with the choice of plasmid 
vector, may have contributed to these contrasting results.
Overexpression of NrdF in the PBE strains had a bacterio­
static effect on S. enterica serovar Typhimurium, which most 
likely would have had a negative impact on its ability to invade 
and replicate in vivo. Such a bacteriostatic effect has been
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FIG. 4. Murine serum immunoglobulin responses against purified Adh, NrdF, and whole-cell STM-1 as determined by ELISA and W estern 
blotting. Day 42 responses (shaded bars) and day 70 responses (white bars) are shown. They axis represents reciprocal titer values. Standard errors 
are indicated. Statistical significance (P <  0.05) determined by comparison to the PBS group is indicated by asterisks. (A) Serum IgM responses 
against purified Adh. (B) Serum IgM responses against purified NrdF. (C) Serum IgG responses against purified Adh. (D) Serum IgG responses 
against purified NrdF. (E) Serum IgG responses against whole-cell STM-1. (F) W estern blot analysis of pooled CBE orally immunized-mouse sera 
(day 42; diluted 1:50) and intraperitoneally immunized-mouse sera (day 42) against M. hyopneumoniae (strain J) whole-cell lysate and purified 
antigen. Lane 1, CBE orally immunized-mouse sera against M. hyopneumoniae whole-cell lysate; lane 2, NrdF intraperitoneally immunized-mouse 
sera against M. hyopneumoniae whole-cell lysate; lane 3, Adh intraperitoneally immunized-mouse sera against M. hyopneumoniae whole-cell lysate; 
lane 4, CBE orally immunized-mouse sera against purified NrdF; lane 5, CBE orally immunized-mouse sera against purified Adh. Molecular mass 
markers in kDa are shown on the right. The filled arrowhead indicates the molecular mass of intact adhesin protein, and the unfilled arrowhead 
indicates the molecular mass of intact NrdF protein.
shown during the expression of a Mycoplasma arthritidis super­
antigen (10), which decreased the viability of the host E. coli 
cells. Therefore the results presented in this study suggest that 
the ability of live, aroA-attenuated S. enterica serovar Typhi- 
murium-based vaccines to replicate and express stably in vivo is 
more important than the level of antigen expression at immu­
nization in generating systemic immune responses.
Characterization of STM-AN1 revealed the presence of the 
nrdF-adh operon within the dps gene, dps encodes a DNA 
binding protein that provides starvation-induced resistance to 
hydrogen peroxide, and expression is upregulated when Sal­
monella comes under oxidative stress during invasion of mac­
rophages (22, 30). In E. coli, dps transcription is regulated in a 
sigma S- and IHF-dependent manner, and the IHF protein has 
been shown to bind upstream of the dps prom oter (3). In this 
study, insertion of the nrdF-adh operon into dps further atten­
uated STM-AN1 in minimal medium supplemented with aro­
mix. Given this result and the importance of dps during mac­
rophage invasion, STM-AN1 was not used in the vaccine trial.
The nrdF-adh operon in STM-AN2 was inserted into glgP. 
This was the only CBE strain for which colonies could not be 
detected in the murine spleen 10 days after in vivo passage. 
Previous infection studies in chickens with a glycogen mutant 
S. enterica serovar Typhimurium had shown that glycogen m e­
tabolism has a minor role in colonization and pathogenesis but 
a more significant role in survival (36); this observation agrees 
with our findings. In this experiment, dual attenuation of aroA 
and glgP reduced the ability of S. enterica serovar Typhimurium 
to survive in vivo. Control of the glycogen metabolism pathway 
is thought to be allosterically regulated by ADP-glucose pyro- 
phosphorylase (40). In E. coli, the binding of CsrA to glgCAP 
transcripts promotes glgCAP mRNA degradation, which inhib­
its glycogen metabolism (4). Transcriptional regulation of the 
operon in E. coli also appears to be controlled by RpoS (23).
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Recent microarray data suggest the glgP transcript was down- 
regulated during Salmonella intracellular infection of murine 
macrophages, although it was below the significant threshold 
value (14). Despite this observation and the reduced ability of 
STM-AN2 to survive in the spleen, it was still able to elicit an 
antigen-specific IgG response.
The position of the nrdF-adh operon in STM-AN3 was able 
to be identified; however, the sequence did not match any 
known Salmonella sequence. The putative open reading frame 
(oifl) driving expression of the antigens had 100% amino acid 
homology to a hypothetical protein from the plant pathogen R. 
solanacearum (42) and a 99% match to a hypothetical protein 
from the human pathogen R. pickettii. Analysis of the trans­
lated sequence using the Pfam and Expasy databases revealed 
no matches with known proteins. As this sequence has not 
previously been reported in Salmonella, and given the strain’s 
ability to survive in vivo, it is unlikely to be critical for patho­
genesis.
STM-AN4, which contains the nrdF-adh operon inserted 
within the conjugal-transfer gene tral, displayed significant IgG 
titers after intranasal challenge, tral encodes OriT nickase/ 
helicase (34) and catalyzes the unwinding of the DNA duplex 
while also acting as a sequence-specific DNA transesterase that 
provides the site/strand-specific nick required to initiate DNA 
transfer (32). Microarray analysis perform ed on the S. enterica 
serovar Typhimurium transcriptome during intracellular infec­
tion of murine macrophages did not examine tral transcript 
levels; however, the conjugal-transfer genes on either side 
(trbH and traX) both displayed significantly elevated transcript 
levels (14), suggesting that tral may also be upregulated during 
in vivo infection.
The importance of in vivo expression is further highlighted 
by the fact that STMl-sspA, which is upregulated in vivo (48), 
produced the only statistically significant CBE-generated re­
sponse at day 42 against either Adh or NrdF. The expression of 
sspA in E. coli is induced during stationary phase while the 
bacterium is undergoing starvation for either carbon, amino 
acids, nitrogen, or phosphate (49). It has been previously dem­
onstrated that S. enterica serovar Typhimurium aroA, express­
ing tetanus toxoid under the control of either single-copy 
(chromosomal) or multicopy (plasmid) sspAp, can generate 
significant immune responses in mice (48). The use of in vivo- 
inducible promoters for S. enterica serovar Typhimurium ex­
pression of heterologous antigens appears to be a promising 
approach, with the use of other promoters, such as ssaGp and 
pagCp, increasing the immunogenicity of heterologous anti­
gens in murine models in comparison to native constitutive 
promoters (13, 35).
The strains capable of surviving for 10 days in vivo all dis­
played 100% stability of the nrdF-adh operon. Husseiny and 
Hensel (26) reported that integration of a heterologous anti­
gen into purD  of S. enterica serovar Typhimurium was stable 
after 9 days in vivo; however, they did not report whether the 
colonies were still capable of expression. All recovered colo­
nies examined in this experiment were capable of heterologous 
antigen expression, demonstrating that the integrated operon 
was highly stable.
Previous studies were conducted using attenuated S. enterica 
serovar Typhimurium aroA to express single NrdF (7, 16, 17) 
or Adh (8 ) antigens. Fagan et al. (16) orally immunized mice
with aroA-attenuated S. enterica serovar Typhimurium SL3261 
expressing NrdF from pHSG398. This construct elicited NrdF- 
specific serum IgA and secretory IgA but failed to produce a 
significant serum IgG response. Chen et al. (7) expressed NrdF 
using plasmid-based prokaryotic and eukaryotic expression 
vectors in S. enterica serovar Typhimurium aroA CS332, and 
they failed to elicit a humoral immune response in orally vac­
cinated mice. However, the splenocytes from the mice pro­
duced a significant level of IFN -7 when stimulated with NrdF, 
indicating the induction of a cell-mediated immune response 
(7). The varying results from this work and the previous trials 
indicate the importance of the choice of expression system and 
Salmonella strain for immunization purposes.
This study has demonstrated the ability of native Salmonella 
promoters to stably express heterologous, single-copy antigens 
from the chromosome and to generate systemic immune re­
sponses via the oral immunization route. The main advantages 
of this technique are that it can be used to generate immune 
responses against bacteriostatic antigens and can do so without 
the use of antibiotic resistance markers. The integration of the 
heterologous expression operon into the S. enterica serovar 
Typhimurium chromosome via a promoter-trapping technique 
allows many novel promoters and attenuation sites to be si­
multaneously assessed. This technique also allows the produc­
tion of stable, cheap, easily administered vaccines that may be 
used in a commercial setting.
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